Reference : The use of an apoE–deficient (apoE-/-) mice model to characterize the therapeutic ben...
Scientific congresses and symposiums : Poster
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/18449
The use of an apoE–deficient (apoE-/-) mice model to characterize the therapeutic benefits of original thromboxane modulators
English
Cherdon, Céline mailto [Université de Liège - ULg > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique >]
Rolin, stephanie mailto [ > > ]
Hanson, Julien mailto [Université de Liège - ULg > Département de pharmacie > Chimie pharmaceutique >]
Duwez, Luc mailto [Université de Liège - ULg > > Services généraux de l'Université >]
Drion, Pierre mailto [Université de Liège - ULg > Services généraux (Faculté de médecine vétérinaire) > Méth. expér. des anim. de labo et éthique en expér. animale >]
Pincemail, Joël mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie cardio-vasculaire >]
de Leval, Laurence mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques - Département des sciences biomédicales et précliniques >]
Defraigne, Jean-Olivier mailto [Université de Liège - ULg > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique >]
Dogné, Jean-Michel mailto [Université de Liège - ULg > Département de pharmacie > Département de pharmacie >]
17-May-2006
Yes
International
Bioforum 2006, Liège, Belgique.
Bioforum
Liège
Belgium
[en] Apo E deficient mice ; thromboxane modulators ; atherosclerosis
[en] The aim of our study was to use an apoE–deficient mouse model to test drugs acting as thromboxane A2 antagonist. Presented here is the “en face” method 6 which allows the evaluation of atherosclerosis lesions development in wild type and APO E-/- mice. This method involves pinning out the aorta and quantifying lesion area as a percentage of total surface area. The use of this mice model offers a unique opportunity to characterize the therapeutic benefits of pharmacologicals agents designed in our laboratory of which antioxidants and thromboxane modulators. The pharmacological characterization of BM-573 as potential antiatherosclerotic agent will also be discussed
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
Researchers ; Professionals
http://hdl.handle.net/2268/18449

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
bioforum 2006.pdfPublisher postprint8.82 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.